- Home
- TPG vs CORT Comparison
TPG vs CORT Comparison
Compare TPG & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPG
- CORT
- Stock Information
- Founded
- TPG 1992
- CORT 1998
- Country
- TPG United States
- CORT United States
- Employees
- TPG N/A
- CORT N/A
- Industry
- TPG Investment Managers
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- TPG Finance
- CORT Health Care
- Exchange
- TPG Nasdaq
- CORT Nasdaq
- Market Cap
- TPG 9.1B
- CORT 7.6B
- IPO Year
- TPG 2022
- CORT N/A
- Fundamental
- Price
- TPG $58.52
- CORT $69.36
- Analyst Decision
- TPG Buy
- CORT Strong Buy
- Analyst Count
- TPG 13
- CORT 4
- Target Price
- TPG $64.17
- CORT $138.25
- AVG Volume (30 Days)
- TPG 1.8M
- CORT 628.8K
- Earning Date
- TPG 11-03-2025
- CORT 10-29-2025
- Dividend Yield
- TPG 2.99%
- CORT N/A
- EPS Growth
- TPG N/A
- CORT N/A
- EPS
- TPG N/A
- CORT 1.11
- Revenue
- TPG $3,887,230,000.00
- CORT $716,080,000.00
- Revenue This Year
- TPG N/A
- CORT $30.62
- Revenue Next Year
- TPG $24.40
- CORT $37.68
- P/E Ratio
- TPG N/A
- CORT $62.24
- Revenue Growth
- TPG 43.35
- CORT 25.71
- 52 Week Low
- TPG $37.52
- CORT $33.66
- 52 Week High
- TPG $72.98
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- TPG 45.46
- CORT 44.94
- Support Level
- TPG $57.25
- CORT $68.82
- Resistance Level
- TPG $62.10
- CORT $72.52
- Average True Range (ATR)
- TPG 1.63
- CORT 1.62
- MACD
- TPG -0.59
- CORT -0.09
- Stochastic Oscillator
- TPG 21.22
- CORT 33.51
About TPG TPG Inc.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.